Product Program year 2021 Source: CMS Open Payments

Loteprednol Etabonate

Drug Ophthalmology

NDC 68682-299-05

Open in the dashboard

General payments

$13,937

925 payments

Research payments

$0

0 payments

Through program year 2021, $13,937 in general payments and $0 in research payments were reported against Loteprednol Etabonate (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2021 General $11,809 786
2020 General $2,128 139

Breakdown

Who paid General payments · program years 2020–2021
  1. Bausch & Lomb, a division of Bausch Health US, LLC $13,937 925 payments
Top recipients General payments · program year 2021
  1. Spencer Moy Optometrist · Brooklyn, NY $523 4% · 48 payments
  2. Kristina Lovinggood Optometrist · Selma, AL $284 2% · 17 payments
  3. Melissa Curl Optometrist · Hoover, AL $122 1% · 10 payments
  4. Glen Lojka Optometrist · Ellisville, MO $121 1% · 12 payments
  5. Ansel Johnson Optometrist · Blue Island, IL $118 <1% · 6 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Optometrist $11,277 95% · 383 practitioners
  2. Optometrist, Corneal and Contact Management Optometrist $384 3% · 13 practitioners
  3. Optometrist, Pediatrics Optometrist $94 <1% · 4 practitioners
  4. Ophthalmology $35 <1% · 2 practitioners
  5. Optometrist, Vision Therapy Optometrist $13 <1% · 1 practitioner

The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. Missouri $2,285 19% · 64 recipients
  2. Illinois $2,228 19% · 72 recipients
  3. Alabama $1,603 14% · 39 recipients
  4. North Carolina $1,255 11% · 39 recipients
  5. Texas $1,131 10% · 60 recipients

The top 5 of 21 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

205,828

Prescriptions dispensed, refills included

Drug cost

$45,423,577

Paid at the pharmacy, in all

Medicare Part D drugs matched to LOTEPREDNOL ETABONATE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Loteprednol Etabonate Same name 4,775 136,551 $21,865,517
Lotemax Sm Loteprednol Etabonate Same name 878 38,319 $10,103,791
Eysuvis Loteprednol Etabonate Same name 364 14,398 $7,307,604
Lotemax Loteprednol Etabonate Same name 367 7,818 $2,995,003
Alrex Loteprednol Etabonate Same name 205 6,098 $2,324,058
Inveltys Loteprednol Etabonate Same name 79 2,644 $827,604

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 484 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
David Mora Optometry TX 1,507 $560,060 None on record
Jeremy Cotliar Ophthalmology NY 1,179 $562,789 None on record
Cuong-Dung DO Ophthalmology CA 1,028 $331,983 None on record
Alberto Ortiz-Arroyo Ophthalmology PR 975 $148,924 None on record
Saveren Scannapiego Ophthalmology NJ 915 $165,779 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 484 with Patron
925 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record